Munich - Delayed Quote EUR

OKYO Pharma Ltd (OK11.MU)

1.2900
+0.1200
+(10.26%)
At close: April 24 at 8:08:08 AM GMT+2
Currency in USD All numbers in thousands
Download
Breakdown
TTM
3/31/2024
3/31/2023
3/31/2022
3/31/2021
Operating Expense
15,749.7320
15,749.7320
13,187.2000
6,217.5660
3,366.2060
Operating Income
-15,749.7320
-15,749.7320
-13,187.2000
-6,217.5660
-3,366.2060
Net Non Operating Interest Income Expense
-1,053.3130
-1,053.3130
-96.6870
--
-1.1230
Other Income Expense
--
--
--
--
-11.1720
Pretax Income
-16,803.0450
-16,803.0450
-13,283.8870
-6,217.5660
-3,378.5010
Tax Provision
22.4160
22.4160
-12.2020
-786.5210
-24.9940
Net Income Common Stockholders
-16,825.4610
-16,825.4610
-13,271.6850
-5,431.0450
-3,353.5070
Diluted NI Available to Com Stockholders
-16,825.4610
-16,825.4610
-13,271.6850
-5,431.0450
-3,353.5070
Basic EPS
-0.61
-0.57
-0.61
-0.36
-0.32
Diluted EPS
-0.61
-0.57
-0.61
-0.36
-0.32
Basic Average Shares
22,257.0580
29,343.7270
22,257.0580
15,064.8130
10,350.2710
Diluted Average Shares
22,257.0580
29,343.7270
22,257.0580
798,259.3560
10,350.2710
Total Operating Income as Reported
--
--
--
--
-4,133.3498
Total Expenses
15,749.7320
15,749.7320
13,187.2000
6,217.5660
3,366.2060
Net Income from Continuing & Discontinued Operation
-16,825.4610
-16,825.4610
-13,271.6850
-5,431.0450
-3,353.5070
Normalized Income
-16,825.4610
-16,825.4610
-13,271.6850
-5,431.0450
-3,342.4176
Interest Expense
1,053.3130
1,053.3130
96.6870
--
1.1230
Net Interest Income
-1,053.3130
-1,053.3130
-96.6870
--
-1.1230
EBIT
-15,749.7320
-15,749.7320
-13,187.2000
-6,217.5660
-3,377.3780
EBITDA
-15,745.8660
-15,745.8660
-13,183.4030
-6,215.2350
-3,364.2670
Reconciled Depreciation
3.8660
3.8660
3.7970
2.3310
13.1110
Net Income from Continuing Operation Net Minority Interest
-16,825.4610
-16,825.4610
-13,271.6850
-5,431.0450
-3,353.5070
Total Unusual Items Excluding Goodwill
--
--
--
--
-11.1720
Total Unusual Items
--
--
--
--
-11.1720
Normalized EBITDA
-15,745.8660
-15,745.8660
-13,183.4030
-6,215.2350
-3,353.0950
Tax Rate for Calcs
0.0003
0.0003
0
0.0001
0
Tax Effect of Unusual Items
--
--
--
--
-0.0826
3/31/2021 - 7/1/2022

Upgrade to begin using 40 years of financial statements and get so much more.

Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.

Upgrade

Related Tickers

ADAG Adagene Inc.
1.3900
-2.80%
 
PEPG PepGen Inc.
1.6800
+4.35%
 
NGNE Neurogene Inc.
15.37
-0.45%
 
REVB Revelation Biosciences, Inc.
2.9300
+3.53%
 
PRQR ProQR Therapeutics N.V.
1.5400
+6.21%
 
TSHA Taysha Gene Therapies, Inc.
1.8200
0.00%
 
BCTX BriaCell Therapeutics Corp.
6.03
+11.05%
 
EVGN Evogene Ltd.
1.1100
+1.83%
 
FATE Fate Therapeutics, Inc.
1.3500
+1.50%
 
PRTG Portage Biotech Inc.
9.27
+3.23%